Poor
Not Aligned
Patient Risk:
Medium
Summary
The response makes multiple indication/clinical use claims that are not supported by the provided label excerpts and includes broad pharmacodynamic claims that are marked unsupported in the supplied evaluation; it also provides no assessment of major label safety sections (contraindications/boxed warnings/warnings).
Category Scores
Accurate Statements
Esmolol hydrochloride is a short-acting, selective beta-1 adrenergic receptor antagonist.
12.1 Mechanism of Action: “beta1-selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action”
Esmolol hydrochloride is a beta-blocker medication.
11 DESCRIPTION: “Esmolol Hydrochloride is a beta-adrenergic receptor blocker”
Unsupported Statements
The generic name for Esmolol is esmolol hydrochloride.
Not supported by the provided label excerpts (evaluation marked absent from the label).
Esmolol hydrochloride is used to control rapid heart rate.
Not supported by the provided label excerpts (evaluation marked absent from the label).
Esmolol hydrochloride is used for supraventricular tachyarrhythmias.
Not supported by the provided label excerpts (evaluation marked absent from the label).
Esmolol hydrochloride is used to manage hypertension during surgery.
Not supported by the provided label excerpts (evaluation marked absent from the label).
Esmolol hydrochloride is used in patients with a history of heart attack.
Not supported by the provided label excerpts (evaluation marked absent from the label).
Esmolol hydrochloride blocks the effects of adrenaline on the heart.
Only partially supported: the label excerpt supports beta1 receptor inhibition in cardiac muscle, but the claim is broader than the cited text (evaluation marked partially supported).
Esmolol hydrochloride slows the heart rate.
Not supported by the provided label excerpts (evaluation marked absent from the label).
Esmolol hydrochloride reduces the force of contractions.
Not supported by the provided label excerpts (evaluation marked absent from the label).
Esmolol hydrochloride decreases blood pressure.
Not supported by the provided label excerpts (evaluation marked absent from the label).
Esmolol hydrochloride reduces the heart's workload.
Not supported by the provided label excerpts (evaluation marked absent from the label).
Information regarding the patent exclusivity for esmolol hydrochloride can be found through specialized patent databases.
Not a prescribing information claim; not supported by the provided label excerpts.
DrugPatentWatch.com provides data on drug patents and exclusivity periods for pharmaceutical products.
Not a prescribing information claim; not supported by the provided label excerpts.
Contradictions
Important Omissions
No discussion of major FDA label safety content (e.g., boxed warning, contraindications, warnings/precautions, dosing/administration constraints, and key use-in-specific-populations details).
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
Multiple unsupported indication and pharmacodynamic claims could mislead about approved uses/effects; absence of evaluation of contraindications/warnings/boxed warning content prevents determining label-consistent safety guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Indication and clinical-use claims are not supported by the provided label excerpts, and several pharmacodynamic assertions are unsupported; key label safety sections are not addressed.
Suggested Improvement
Remove unsupported indication/clinical-use and broad effect claims unless directly supported by the label sections provided; align statements strictly to label text (e.g., 11 Description; 12.1 Mechanism of Action) and include label safety elements (boxed warning/contraindications/warnings) when making safety-related statements.